ORISCON BIOTECH INDIA PRIVATE LIMITED

2012-01-24T05:32:00.000-08:00

ओरिस्कन् बायोटेक इन्डिया प्राइवेट लिमिटेड

( कंपनी अधिनियम 1956 के अंतर्गत स्थापित )

ORISCON BIOTECH (I) PVT LTD

Regd. Office : Plot No: C- 80, Ganesh Nagar,Pandav Nagar Complex, New Delhi -110092,

Corporate Office:Plot No: C-31/32, G-3, Ganesh Nagar, Pandav Nagar Complex, New Delhi -110092 ,
Phone No: 011- 22486954

Email

orisconbiotech@gmail.com

( Click here )

Oriscon'sVision

"We are a company registered under the Indian Companies Act 1956 in the year 2006 at New Delhi . At Oriscon Biotech india private limited Our philosophy is to provide economically priced good quality Pharmaceutical Products to the humankind at large. We also believe that there should be no compromise on the health of a human being. Our vision is to become a significant major Pharmaceutical Company in INDIA by providing good quality & affordable economical medicine for the treatment of all types of life threatening disease. "

Oriscon'sMission

"We are still in the process of building our own fully integrated, commercial stage bio pharmaceutical company that invents, develops and markets safe and effective small molecule drugs to treat patients with debilitating and life - threatening diseases primarily in cancer , tuberculosis and kala-azar & inflammation . We intend to make & accomplish this through the following innovative strategies:

“We are meticulously making available pharmaceutical products , and constantly improving existing product mix, thereby carving out a niche for ourselves in the field of pharmaceutical marketing in INDIA. We shall provide total customer satisfaction through excellent quality control along with most economically priced Pharmaceutical Products”

Standard Quality policy of the Company :

Your company is dedicated to provide consistently High Quality range of Products in the field of human Health care to the satisfaction of medical community and all consumers at most economical price. This is being achieved by cumulative efforts from the top to bottom by maintaining quality control aimed at Defect prevention rather than Defect Detection".

Cost-effective Marketing strategy :

Your company's track record of development, particularly in the nick area of improved cost-beneficial marketing strategy for latest various drugs molecules is excellent. It also provides a wide variety of generic drugs along with a range of sophisticatedly made drug formulations at most economical price.

All of you must remember," Success depends on your ability to shape the future by anticipating and responding to change. You should also know that you have never been better positioned to achieve this".

====================================================================

Chairman & Managing Director's Message:

To,

All Promoters/Members " Oriscon Biotech (I) Pvt Ltd "

It has been a very eventful year for the company I say this confidently because: Your Company has a robust financial position considering the fact that capital of the company has grown into Six Folds within a short span of four years ( From INR 40.00 Lacs to INR 2.50 crores) ,which provides the means to deliver the strategy. Investment return for the year has been satisfactory as it is evident from the fact that your Company has already paid a return of 14% to all the Promoters / Members as per the respective agreements according to their share holdings.

SUBSIQUENTLY THE VALUE OF THE SHARES OF THE COMPANY HAS SEEN A SIX FOLD INCREASE SINCE THE INCEPTION OF THE COMPANY,

Certainly, the competition is intensifying in all activities as the generic medicine business of institutional supply progresses towards market dominated by big pharmaceutical players. Presently our activities are in both segments of marketing in different States & Institutional supply and hope that in next year the present annual figures should surpass those for current year.

Finally, may I express my gratitude to my fellow directors for their guidance, sincerity and application during the past year .Your company intend to keep it so in future also.

For and on behalf of the Board

Priya Ranjan Shrivastava

( Chairman & Managing Director)

cmd@orisconbiotech.com

=================================================================================================

Our Recruitment Process :

The recruitment and selection is the major function of the human resource department and recruitment process is the first step towards creating the competitive strength and the strategic advantage for the organisations.

Recruitment process involves a systematic procedure from sourcing the candidates to arranging and conducting the interviews and requires many resources and time. A general recruitment process is as follows:

The vacancy Identifying :

The recruitment process begins with the human resource department receiving requisitions for recruitment from any department of the company. These contain:

1. Identify vacancy

2. Prepare job description and person specification

3. Advertising the vacancy

4. Managing the response

5. Short-listing

6. Arrange interviews

7. Conducting interview and decision making

The recruitment process is immediately followed by the selection process i.e. the final interviews and the decision making, conveying the decision and the appointment formalities.

If you are interested in joining us, send in a mail to : orosconbiotech@gmail.com

hrd@orisconbiotech.com

===========================================================================

STEPS TO STRENGTHEN :

Your company need to attain the right product-mix for sustained future growth. Core competencies will play an important role in determining the future prospects of your company among pharmaceutical companies in the post product-patent regime after 2005.

Oriscon Biotech (I) Pvt Ltd, in an effort to consolidate its position, will have to increasingly look at merger and acquisition options of either companies or products . this would help your company to offset loss of new product options, improve its R&D efforts and improve distribution to penetrate markets .

LOGISTIC STRENGTHEN :

However when a new vendor is to be approved as the situations demand Oriscon Biotech Private Limited has written down procedures as per law for approval of new vendors. Stability study of the product and its quality is done when there is a change in manufacturer / vendor / supplier of critical materials like active ingredients of pharmaceutical molecule , Primary Packing materials & any critical equipments.

All finished products are tested to the specified standards as per norms given in specification. All the products of our company are subjected to chemical and microbiological analysis for total counts of microbes and absence of pathogenic organisms. The products are released for dispatch after compliance of the products to the specified standards.

====================================================================

We have already tied-up with the manufacturer who can provide quality products at most economical price with excellent service having G.M.P standard as required by W.H.O.

Our Company is well equipped for quick manufacturing and supplying to the concerned Distributors (Carrying and Forwarding Agents) in the capital of the Marketing territory.

OUR COMPANY is intended to make available life saving medicines at the most economical price to the needy poor patients who are unable to treat the disease like : Malaria , Kala-azar , Dengue , Tuberculosis besides purchasing of costly life savings antibiotics.

Every Company has to concentrate on both fronts the present to continue its operation successfully at the current level in the stronghold area for generating operational profit ,and the future to prepare itself for the challenges lying ahead. Since Bihar is considered a Gold Mine for Pharmaceutical Business due to very high rate of consumption of medicine by per capita population. This is the reason that all Pharma Companies have started their marketing venture from Bihar.

Therefore, this aspects of marketing is on our plus side ; considering the facts that promoters of this company are having eighteen years of Marketing Experience of each and every town of Bihar & Jharkhand. Our company has set forth the target of achieving Rs.2 Crores sales in the year (2011-12) with a team of 25 Medical Representatives, Two Zonal Sales Managers & Five Regional Managers.

====================================================================

THE GROWTH SCENARIO

India's US$ 3.1 billion pharmaceutical industry is growing at the rate of 18 percent per year. It is one of the largest and most advanced among the developing countries.Over 20,000 registered pharmaceutical manufacturers exist in the country. The domestic pharmaceuticals industry output is expected to exceed Rs460 billion in the financial year (2011-12), which accounts for merely 2.3% of the global pharmaceutical sector.

We intend to make & accomplish this through the following innovative strategies:

We are meticulously making available pharmaceutical products,and constantly improving existing product mix, thereby carving out a niche for ourselves in the field of pharmaceutical marketing in INDIA. We shall provide total customer satisfaction through excellent quality control with economically priced Pharmaceutical Products"

OPERATIONS :

Your Company is dealing in Institutional supply of Pharmaceuticals Generic products with the various procurement departments. Your Company would explore the possibility of entering into the marketing of 30 more Branded Pharmaceutical Products under loan license facility in various headquarters in Bihar & Jharkhand.At present we are Marketing 20 Branded Products.

====================================================================

ADVANTAGE :

Competent Workforce: Your Company has a pool of personnel with high managerial and technical competence as also skilled workforce. It has an educated hard working field force personal in the marketing area and professional environment to work for.

Cost-effective : Your Company's track record of development, particularly in the area of improved cost-beneficial marketing strategy for various drug molecules is excellent. It provides a wide variety of generic drugs and sophisticatedly made drug formulations.

Technology: Your Company has intended to develop a good marketing network of world-class by investing a lot to establish and strengthen the area in Information Technology.

Pharma Marketing: Your Company is committed to tap the market economy of pharmaceutical sector and . Above all, it has a clear cut strategy to take a big share of pharma market, which is continuously growing at the rate of 18% annually.

Consolidation: For the first time in many years, your company is finding great opportunities in pharmaceutical marketing . The process of consolidation, which has become a generalized phenomenon in the world pharmaceutical industry, has started taking place in India.

====================================================================

OUTLOOK

In the year 2010-11 your Company has declared the dividend of 14% (inclusive of dividend tax). The right shares issued during March ( 2010 – 11 ) also qualify for full year’s dividend. The Company’s financial results for the financial year ended 31st March 2011 are summarized below:

The authorized capital of the company has increased from Rs.40,00,000/-( Rupees Forty Lacs only) to Rs.2,00,00,000/- (Rupees Two Crores only) by creation of 16,00,000 (Sixteen Lacs) New equity shares of Rs.10/- (Rupees Ten only) each. Consequently, Clause V of the Memorandum of Association and Article 3 (a) of the Articles of Association of the Company is proposed to be altered.

A Copy of Memorandum and Articles of Association of the Company together with the proposed alteration will be made available for inspection by the Members of the Company at its Registered office between 11:00 a.m. and 1:00 p.m. on any working day of the Company till the date of Annual General Meeting.

In terms of the provisions of Section (s) 16, 31and 94 consent of the Members is required for any alteration in Memorandum and Articles of Association of the Company. The Board recommends the Resolutions for your approval.

Under section 293(1)(d) of the Companies Act, 1956, the Board of Directors cannot except with the consent of the Company borrow moneys apart from temporary loans obtained from the Company’s bankers in the ordinary course of business in excess of the aggregate of paid-up capital and free reserves of the Company, that is to say, reserves not set apart for any specific purpose.

The members of the Company at the Extra-ordinary General meeting held on April 20, 2010 by Special resolution authorised Board of Directors of the Company to borrow up to a limit of Rs. 2 crores. In view of increased volume of business envisaged in the forthcoming months, it is proposed to authorise the Board to borrow up to Rs2 crores and for this purpose approval of the members is sought under Section 293(1)(d) of the Act.

===========================================================================

BOARD OF DIRECTORS
Mr. P. R. Shrivastava Mr. Kamlendra Kumar	Chairman & Managing Director Joint Director
Dr. A. K. Singh	Human Resources Director
Mr. J. Sah	Investment committee Director
Mr. A. C. Verma	Audit Committee Director
Mr. M. K. Thakur	Legal Affairs Director
Mr. M. Kumar	Welfare committee Director
Dr. B. K. Gupta	Product Research Director
Mr. K. Mishra	Corporate Affairs Director
Mr. U. K. Thakur	Non executive Independent Director
Mr. T. Kumar	Audit Committee Member

Scope of Business : To manufacturing and marketing of pharmaceutical drugs, Institutional Supply and over-the-counter drugs under loan license facility.

Website : www.orisconbiotech.com

COMPANY SECRETARY:-M/S Arun Associates, New Delhi

BANKERS :-Punjab National Bank & AXIS Bank Ltd

AUDITORS: M/S Jha Shailendra & Associates,Chartered Accountants MR. S. K. JHA (FCA ).

====================================================================